Propagation of CD4+ T cells specific for HIV type 1 envelope gp120 from chronically HIV type 1-infected subjects

AIDS Research and Human Retroviruses

Volumn 19, Issue 9, 2003, Pages 793-806

  Cohen, Sandra ^a   Tuen, Michael ^a   Hioe, Catarina E ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAMMA INTERFERON; GLYCOPROTEIN GP 120; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANTIGEN RECOGNITION; ARTICLE; CELL LINE; CELL SPECIFICITY; CELLULAR IMMUNITY; CROSS REACTION; EPITOPE MAPPING; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSTIMULATION; IN VITRO STUDY; INTERFERON PRODUCTION; LYMPHOCYTE PROLIFERATION; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; T LYMPHOCYTE; VIRUS ISOLATION; VIRUS STRAIN;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AMINO ACID SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; EPITOPE MAPPING; EPITOPES, T-LYMPHOCYTE; HIV ENVELOPE PROTEIN GP120; HIV-1; HLA-DR ANTIGENS; HUMANS; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; MOLECULAR SEQUENCE DATA;

EID: 0141593481     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922203769232593     Document Type: Article

References (47)

1. + T cell-mediated antiviral protection. J Immunol 1999;162:2867-2874.
2. + T-cell mechanisms in the control of respiratory virus infections. Immunol Rev 1997;159:105-117.
3. + T cell responses during chronic virus infection prevents neutralizing antibody responses against virus escape mutants. J Exp Med 2001;193:297-305.
4. Zajac AJ, Blattman JN, Murali-Krishna K, Sourdive DJ, Suresh M, Altman JD, and Ahmed R: Viral immune evasion due to persistence of activated T cells without effector function [see comments]. J Exp Med 1998;188:2205-2213.
5. + T-cell responses against malaria liver stages. Nat Med 2002;8:166-170.
6. + T cells in controlling retrovirus replication and spread in persistently infected mice. J Virol 1998;72:6559-6564.
7. Kalams SA, Buchbinder SP, Rosenberg ES, Billingsley JM, Colbert DS, Jones NG, Shea AK, Trocha AK, and Walker BD: Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection. J Virol 1999;73:6715-6720.
8. + T cell responses associated with control of viremia [see comments]. Science 1997;278:1447-1450.
9. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression [see comments]. Nat Med 1999;5:518-525.
10. + T-cell responses: Relationship to viral load in untreated HIV infection. J Virol 2001;75:11983-11991.
11. Appay V, Papagno L, Spina CA, Hansasuta P, King A, Jones L, Ogg GS, Little S, McMichael AJ, Richman DD, and Rowland-Jones SL: Dynamics of T cell responses in HIV infection. J Immunol 2002;168:3660-3666.
12. + T cell proliferative responses to gp120. AIDS Res Hum Retroviruses 2000;16:893-905.
13. + T cells by antibodies specific for the CD4 binding domain of gp120. J Virol 2001;75:10950-10957.
14. Durinovic-Bello I, Steinle A, Ziegler AG, and Schendel DJ: HLA-DQ-restricted, islet-specific T-cell clones of a type I diabetic patient: T-cell receptor sequence similarities to insulitis-inducing T-cells of nonobese diabetic mice. Diabetes 1994;43:1318-1325.
15. + Th1 cells kill Burkitt's lymphoma cells. J Immunol 2002;169:1593-1603.
16. Dadmarz RD, Ordoubadi A, Mixon A, Thompson CO, Barracchini KC, Hijazi YM, Steller MA, Rosenberg SA, and Schwartzentruber DJ: Tumor-infiltrating lymphocytes from human ovarian cancer patients recognize autologous tumor in an MHC class II-restricted fashion. Cancer J Sci Am 1996;2:263.
17. Peiper M, Sato T, Streichert T, Eisenberger CF, Knoefel WT, and Izbicki JR: Cytotoxic T lymphocyte mediated recognition of human pancreatic cancer cells. Int J Cancer 2002;99:88-92.
18. + T lymphocyte lines from HIV-1-seropositive patients. J Infect Dis 1995;171:1420-1430.
19. + T-cell responses to CMV in HIV-1-infected subjects. Virology 2001;279:459-470.
20. Wahren B, Morfeldt-Mansson L, Biberfeld G, Moberg L, Sonnerborg A, Ljungman P, Werner A, Kurth R, Gallo R, and Bolognesi D: Characteristics of the specific cell-mediated immune response in human immunodeficiency virus infection. J Virol 1987;61:2017-2023.
21. Borkowsky W, Krasinski K, Moore T, and Papaevangelou V: Lymphocyte proliferative responses to HIV-1 envelope and core antigens by infected and uninfected adults and children. AIDS Res Hum Retroviruses 1990;6:673-678.
22. + T cell proliferation. Proc Natl Acad Sci USA 2001;98:13878-13883.
23. Cheynier R, Henrichwark S, Hadida F, Pelletier E, Oksenhendler E, Autran B, and Wain-Hobson S: HIV and T cell expansion in splenic white pulps is accompanied by infiltration of HIV-specific cytotoxic T lymphocytes. Cell 1994;78:373-387.
24. + T lymphocytes during HIV-1 infection. Clin Exp Immunol 1994;95:436-441.
25. - T-cells. Clin Immunol Immunopathol 1995;77:33-41.
26. + T cells. Nature 2002;417:95-98.
27. + T cells by primary HIV-1 infection: Potential mechanism of vaccine failure. J Immunol 1997;158:807-815.
28. Fenoglio D, Li Pira G, Lozzi L, Bracci L, Saverino D, Terranova P, Bottone L, Lantero S, Megiovanni A, Merlo A, and Manca F: Natural analogue peptides of an HIV-1 GP120 T-helper epitope antagonize response of GP120-specific human CD4 T-cell clones. J Acquir Immune Defic Syndr 2000;23:1-7.
29. + cytotoxic T-cell clone, induced by a natural HIV type 1 variant peptide. J Virol 2000;74:2121-2130.
30. Wahren B, Bratt G, Persson C, Leven B, Hinkula J, Gilljam G, Nordlund S, Eriksson L, Volvovitz F, Broliden PA, et al.: Improved cell-mediated immune responses in HIV-1-infected asymptomatic individuals after immunization with envelope glycoprotein gp160. J Acquir Immune Defic Syndr 1994;7:220-229.
31. Leandersson AC, Bratt G, Hinkula J, Gilljam G, Cochaux P, Samson M, Sandstrom E, and Wahren B: Induction of specific T-cell responses in HIV infection. AIDS 1998;12:157-166.
32. 3 (AIDS Clinical Trials Group Study 246/946). AIDS Res Hum Retroviruses 2001;17:1371-1378.
33. Jones GJ, von Hoegen P, Weber J, and Rees AD: Immunization with human immunodeficiency virus type 1 rgp120W61D in QS21/MPL adjuvant primes T cell proliferation and C-C chemokine production to multiple epitopes within variable and conserved domains of gp120W61D. J Infect Dis 1999;179:558-566.
34. Manca F, Habeshaw J, and Dalgleish A: The naive repertoire of human T helper cells specific for gp120, the enyelope glycoprotein of HIV. J Immunol 1991;146:1964-1971.
35. + T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing. Proc Natl Acad Sci USA 2001;98:4587-4592.
36. Godkin AJ, Smith KJ, Willis A, Tejada-Simon MV, Zhang J, Elliott T, and Hill AV: Naturally processed HLA class II peptides reveal highly conserved immunogenic flanking region sequence preferences that reflect antigen processing rather than peptide-MHC interactions. J Immunol 2001;166:6720-6727.
37. Pape GR, Gerlach TJ, Diepolder HM, Gruner N, Jung M, and Santantonio T: Role of the specific T-cell response for clearance and control of hepatitis C virus. J Viral Hepat 1999;6(Suppl 1):36-40.
38. Jennings SR, Bonneau RH, Smith PM, Wolcott RM, and Chervenak R: CD4-positive T lymphocytes are required for the generation of the primary but not the secondary CD8-positive cytolytic T lymphocyte response to herpes simplex virus in C57BL/6 mice. Cell Immunol 1991;133:234-252.
39. Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, and Riddell SR: Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: Correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994;83:1971-1979.
40. + T cell counts and recurrent retinitis. J Infect Dis 2001;183:1285-1289.
41. Mazzoli S, Trabattoni D, Lo Caputo S, Piconi S, Ble C, Meacci F, Ruzzante S, Salvi A, Semplici F, Longhi R, Fusi ML, Tofani N, Biasin M, Villa ML, Mazzotta F, and Clerici M: HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals [see comments]. Nat Med 1997;3:1250-1257.
42. Papasavvas E, Ortiz GM, Gross R, Sun J, Moore EC, Heymann JJ, Moonis M, Sandberg JK, Drohan LA, Gallagher B, Shull J, Nixon DF, Kostman JR, and Montaner LJ: Enhancement of human immunodeficiency virus type 1-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption. J Infect Dis 2000;182:766-775.
43. + T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy. J Infect Dis 2000;181:1264-1272.
44. Davey RT Jr, Bhat N, Yoder C, Chun TW, Metcalf JA, Dewar R, Natarajan V, Lempicki RA, Adelsberger JW, Miller KD, Kovacs J A, Polis MA, Walker RE, Falloon J, Masur H, Gee D, Baseler M, Dimitrov DS, Fauci AS, and Lane HC: HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 1999;96:15109-15114.
45. Smith D, Gow I, Colebunders R, Weller I, Tchamouroff S, Weber J, Boag F, Hales G, Adams S, Patou G, and Cooper DA: Therapeutic vaccination (p24-VLP) of patients with advanced HIV-1 infection in the pre-HAART era does not alter CD4 cell decline. HIV Med 2001;2:272-275.
46. Sandstrom E and Wahren B: Therapeutic immunisation with recombinant gp160 in HIV-1 infection: A randomised double-blind placebo-controlled trial. Nordic VAC-04 Study Group. Lancet 1999;353:1735-1742.
47. Birx DL, Loomis-Price LD, Aronson N, Brundage J, Davis C, Deyton L, Garner R, Gordin F, Henry D, Holloway W, Kerkering T, Luskin-Hawk R, McNeil J, Michael N, Foster Pierce P, Poretz D, Ratto-Kim S, Renzullo P, Ruiz N, Sitz K, Smith G, Tacket C, Thompson M, Tramont E, Yangco B, Yarrish R, and Redfield RR: Efficacy testing of recombinant human immunodeficiency virus (HIV) gp160 as a therapeutic vaccine in early-stage HIV-1-infected volunteers: rgp160 Phase II Vaccine Investigators. J Infect Dis 2000;181:881-889.